Senior Director
Gilead Sciences, Inc.
Dr. Chan is Senior Director in the U.S. Medical Affairs group at Gilead Sciences, Inc. in Foster City, CA, where she focuses on launch strategies for assets in the Gilead Oncology portfolio, including Trodelvy and the investigational agent, magrolimab. Previously, Dr. Chan served as the U.S. Medical Affairs lead for launch of the CAR T-cell therapy, Tecartus, for patients with relapsed or refractory mantle cell lymphoma and led post-marketing research studies around the PI3K inhibitor, Zydelig. Prior to joining Gilead and Kite, Dr. Chan directed an academic research laboratory at the Indiana University School of Medicine focused on the collaboration of the PI3K- and Ras-mediated signaling pathways in oncogenic PTPN11-induced
leukemia.
